Last reviewed · How we verify
placebo /IBI112
IBI112 is an anti-PD-1 monoclonal antibody.
IBI112 is an anti-PD-1 monoclonal antibody. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | placebo /IBI112 |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 ligands and thereby enhancing T cell activation and anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis (PHASE2)
- IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment (PHASE3)
- A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis (PHASE2)
- Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |